Orchid - India Ratings

More documents

Recommendations

Info

The current growth initiatives will mark asignificant transformation of Orchid’s businessRegulated MarketsCurrent programmes will provide entry into the USmarkets progressively from 2003-04, both in bulk andpharmaScale andearningsConsequently, Orchid will achieve high turnover,robust profitability and high growthInnovationOrchid will have patented new drugs from itsdiscovery bases in India and US, with consequentrating for IPROrchid is poised to leverage its high technology infrastructurefor robust growth and profitability, extending the leadershipposition in cephalosporin bulk and formulations19
SummaryRobust performance growth is forecast on the basis of athree pronged strategy, under implementationNCEs from Orchid and Bexelplatforms for outlicensing toMNCs after Phase II clinicalsExport-oriented formulations growthcovering domestic and non-regulatedmarketsUS cephalosporin generics business,with US FDA compliant API andformulation plants20
Page 1 and 2: CONFIDENTIALProfile and StrategyDec
Page 3: Orchid’s web of six core capabili
Page 6 and 7: Orchid’s strategy in 1999 aimed a
Page 8 and 9: Orchid drew up a new business strat
Page 10 and 11: Projects executed / under execution
Page 12 and 13: Performance in 2002-03 will be sign
Page 14 and 15: For the long term, specific project
Page 16 and 17: In research and other knowledge int
Page 18 and 19: The organic strategy is supplemente
Page 22: 21Thank You

Orchid - India Ratings

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?